000 06456nam a22005055i 4500
001 978-1-4419-9695-4
003 DE-He213
005 20140220082803.0
007 cr nn 008mamaa
008 120920s2013 xxu| s |||| 0|eng d
020 _a9781441996954
_9978-1-4419-9695-4
024 7 _a10.1007/978-1-4419-9695-4
_2doi
050 4 _aRC321-580
072 7 _aPSAN
_2bicssc
072 7 _aMED057000
_2bisacsh
082 0 4 _a612.8
_223
100 1 _aGidday, Jeffrey M.
_eeditor.
245 1 0 _aInnate Tolerance in the CNS
_h[electronic resource] :
_bTranslational Neuroprotection by Pre- and Post-Conditioning /
_cedited by Jeffrey M. Gidday, Miguel A. Perez-Pinzon, John H. Zhang.
264 1 _aNew York, NY :
_bSpringer New York :
_bImprint: Springer,
_c2013.
300 _aIX, 699 p. 60 illus., 44 illus. in color.
_bonline resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _atext file
_bPDF
_2rda
490 1 _aSpringer Series in Translational Stroke Research
505 0 _aPreface -- Section I.   Comparative Physiology and Historical Background -- 1. Tolerance, Historical Review -- 2. Anoxia resistance in lower and higher vertebrates -- 3. Hibernation:  A Natural Model of Tolerance to Cerebral Ischemia/Reperfusion -- 4. Preconditioning in the Heart -- Section II.   Conditioning Methods -- 5. Neuroprotection and Physical Preconditioning:  Exercise, Hypothermia, and Hyperthermia -- 6. A New Future in Brain Preconditioning Based on Nutraceuticals:  Focus on α-Linolenic Omega-3 Fatty Acids for Stroke Protection -- 7. Medical Gases for Conditioning:  Volatile Anesthetics, Hyperbaric Oxygen, and Hydrogen Sulfide -- 8. Hypoxic Preconditioning in the CNS -- 9. Pharmacologic Preconditioning -- 10. Surgical Methods to Induce Brain Preconditioning -- Section III. Conditioning Models for Cerebral Ischemia -- 11. Tolerance Against Global Cerebral Ischemia:  Experimental Strategies, Mechanisms, and Clinical Applications -- 12. Preconditioning and Neuroprotection in the Immature Brain -- 13. Conditioning Studies in Focal Cerebral Ischemia:  Model Selection, Physiological Monitoring, and Other Methodological Issues -- 14. Preconditioning for Subarachnoid Hemorrhage -- 15. Preconditioning for Intracerebral Hemorrhage -- 16. The Protective Effects of Ischemic Postconditioning in Experimental Stroke -- Section IV. Mechanisms of Preconditioning -- 17. Synaptic Signaling in Ischemic Tolerance -- 18 -- The Genomics of Preconditioning and Ischemic Tolerance -- 19. How do Subcellular Organelles Participate in Preconditioning-Conferred Neuroprotection? -- 20. Ischemic Preconditioning–Mediated Signaling Pathways Lead to Tolerance Against Cerebral Ischemia -- 21. Preconditioning the Neurovascular Unit:  Tolerance in the Brain’s Non-Neuronal Cells -- Section V.   Other Neurological Disorders -- 22. Preconditioning for Surgical Brain Injury -- 23. Intrinsic Neuroprotection in Traumatic Brain Injury -- 24. Preconditioning for Epilepsy -- 25. Ischemic Pre- and Post-Conditioning in the Retina -- Section VI. Clinical Applications -- 26. Clinical Cerebral Ischemic Preconditioning -- 27. Preconditioning Strategy:  Coronary Bypass, Subarachnoid Hemorrhage, Temporary Proximal Vessel Occlusion in Carotid Revascularization, and Intracranial Aneurysm Surgery -- 28. HBO preconditioning for TBI and Stroke Patients -- 29. Electroacupuncture Preconditioning for Stroke Patients -- 30. Clinical Trials of Ischemic Conditioning -- Epilogue -- Index.    .
520 _aCerebral ischemia from cardiac arrest, stroke, and subarachnoid and intracerebral hemorrhage, together with trauma, epilepsy, and other CNS pathologies, continue to impose immense burdens of morbidity and mortality the world over. Despite many decades of research aimed at understanding the genetic and molecular basis of these pathologies, therapeutics developed on the basis of blocking ‘known’ injury mechanisms can actually claim few clinical successes. The field of CNS “preconditioning” was born from the preclinical finding more than 20 years ago that intentional activation of innate, cytoprotective factors could provide robust protection, or “tolerance” against cerebral ischemic injury.  Herein, up-to-date summaries on all aspects of preconditioning for CNS disease, including the emerging topics of postconditioning and remote pre- and post-conditioning, are provided by the leading scientists in the field. The translational potential of both preclinical and clinical advances is underscored throughout, with the hope of accelerating the bench-to-bedside success of endogenous cytoprotection as a therapeutic strategy.   Jeffrey M. Gidday PhD, Associate Professor of Neurosurgery at Washington University School of Medicine, has been working in the field of CNS preconditioning for 18 years, and has numerous publications on preconditioning-induced protection in the setting of several different cerebral and retinal pathologies.  Miguel A. Perez-Pinzon PhD is Professor of Neurology/Neuroscience, Vice-Chair for Basic Science of Neurology at the University of Miami Miller School of Medicine. He began studies of ischemic preconditioning in 1995 and for many years prior to that worked in the field of anoxia tolerance, publishing close to 50 peer-reviewed articles and many book chapters on these topics. John H. Zhang MD PhD is Professor of Neurosurgery, Anesthesiology, and Physiology, and Vice-Chair of the Basic Science Department at the Loma Linda University School of Medicine. His research interests include stroke and medical gases, and he has published papers related to pre-, post- and remote-conditioning in subarachnoid hemorrhage, focal cerebral ischemia, and neonatal brain injury.
650 0 _aMedicine.
650 0 _aNeurosciences.
650 0 _aNeurology.
650 0 _aNeurobiology.
650 1 4 _aBiomedicine.
650 2 4 _aNeurosciences.
650 2 4 _aNeurology.
650 2 4 _aNeurobiology.
700 1 _aPerez-Pinzon, Miguel A.
_eeditor.
700 1 _aZhang, John H.
_eeditor.
710 2 _aSpringerLink (Online service)
773 0 _tSpringer eBooks
776 0 8 _iPrinted edition:
_z9781441996947
830 0 _aSpringer Series in Translational Stroke Research
856 4 0 _uhttp://dx.doi.org/10.1007/978-1-4419-9695-4
912 _aZDB-2-SME
999 _c94494
_d94494